CRMD - CorMedix, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.2500
+0.0400 (+3.31%)
As of 1:53PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.2100
Open1.1800
Bid1.2300 x 800
Ask1.2400 x 1100
Day's Range1.1100 - 1.2500
52 Week Range0.1700 - 2.4000
Volume2,211,239
Avg. Volume5,347,578
Market Cap106.138M
Beta (3Y Monthly)5.04
PE Ratio (TTM)N/A
EPS (TTM)-0.5480
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Recent Analysis Shows Lantheus, Editas Medicine, CorMedix, DXP Enterprises, Peabody Energy, and CommScope Holding Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE5 days ago

    CorMedix Inc. Clarifies That No New Shares Are Being Issued In Connection With Its Recently Filed Form S-3 Registration Statement

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / October 18, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today clarified that contrary to certain erroneous news reports it is not issuing any new shares in connection with the S-3 filing filed on October 15, 2018. On October 15, 2018, the Company filed a Form S-3 registration statement to register an aggregate of 15,081,634 shares of its common stock issuable upon the exercise of Series B warrants with an exercise price of $1.05 and associated Underwriter warrants with an exercise price of $0.9375, both expiring on August 10, 2022, which were issued in connection with the Company's May 2017 underwritten public offering.

  • Simply Wall St.22 days ago

    What Kind Of Shareholders Own CorMedix Inc (NYSEMKT:CRMD)?

    The big shareholder groups in CorMedix Inc (NYSEMKT:CRMD) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable Read More...

  • ACCESSWIRE2 months ago

    CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 31, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that NYSE Regulation has accepted the Company's plan to regain compliance with the Exchange's continued listing standards set forth in Sections 1003(a)(i-iii) of the NYSE American Company Guide. CorMedix submitted its plan on July 16, 2018, and has been granted a plan period through December 16, 2019. As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2018, CorMedix was notified on June 14, 2018, by the Exchange that the Company was not in compliance with Section 1003(a)(i)-(iii) related to insufficient stockholders' equity.

  • ACCESSWIRE2 months ago

    CorMedix Inc. to Present at The 20th Annual Rodman & Renshaw Global Investment Conference

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 30, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Khoso Baluch, President and Chief Executive Officer, accompanied by Paul Chew, M.D., Chief Medical Officer, will present a corporate overview with a focus on the Company's Neutrolin Phase 3 development program at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4-6, 2018 at the St. Regis New York Hotel in New York City.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of C&J ...

  • Associated Press2 months ago

    CorMedix: 2Q Earnings Snapshot

    On a per-share basis, the Berkeley Heights, New Jersey-based company said it had a loss of 10 cents. The pharmaceutical and medical device company posted revenue of $7,600 in the period. Its adjusted revenue ...

  • ACCESSWIRE2 months ago

    CorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update

    - LOCK-IT-100 trial results positive; trial halted for efficacy - Conference Call today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 14, 2018 / CorMedix Inc. (NYSE American: CRMD), ...

  • ACCESSWIRE2 months ago

    CorMedix Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / CorMedix Inc. (NYSE American: CRMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern Time. ...

  • ACCESSWIRE3 months ago

    CorMedix Inc. to Report Second Quarter 2018 Financial Results on Tuesday, August 14

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 2, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE3 months ago

    Today's Research Reports on Stocks to Watch: USANA Health Sciences and CorMedix

    NEW YORK, NY / ACCESSWIRE / July 26, 2018 / It was a day of gains for both USANA Health Sciences Inc. and CorMedix. USANA reported record results for the second quarter while CorMedix announced the Data Safety Monitoring Board's positive review of the interim analysis of data from the currently ongoing Phase 3 LOCK-IT-100 study for Neutrolin. The company can now submit results to the Food & Drug Administration for review.

  • ACCESSWIRE3 months ago

    Cormedix Inc. Announces Positive Results Of Its Neutrolin(R) Phase 3 Lock-It-100 Study Based On Recommendation By Independent Data Safety Monitoring Board

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / July 25, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the interim analysis of the data from the currently ongoing Phase 3 LOCK-IT-100 study for Neutrolin®. Because the pre-specified level of statistical significance was reached and efficacy had been demonstrated, the DSMB recommended the study be terminated early.

  • ACCESSWIRE3 months ago

    Free Research Reports on CorMedix and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. Markets served include medical, agricultural, environmental, and industrial.Lined up for scanning this morning are the following equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), CorMedix Inc. (NYSE AMER: CRMD), CRISPR Therapeutics AG (NASDAQ: CRSP), and Endocyte Inc. (NASDAQ: ECYT).

  • ACCESSWIRE4 months ago

    Today's Free Research Reports Coverage on CorMedix and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. This Monday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), Corcept Therapeutics Inc. (NASDAQ: CORT), CorMedix Inc. (NYSE AMER: CRMD), and CRISPR Therapeutics AG (NASDAQ: CRSP).

  • ACCESSWIRE4 months ago

    Cormedix Inc. Completes Review and Source Verification of Phase 3 Lock-It 100 Data For Neutrolin(R)

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / June 20, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed its review and source-verification of the data required for the interim analysis of the Phase 3 LOCK-IT 100 study for Neutrolin®. The Company anticipates the database will be locked shortly and transferred to the independent biostatistician for unblinding and analysis. The independent biostatistician will then provide the results to the Data Safety Monitoring Board (DSMB) for its review, which is expected to occur in July 2018.

  • ACCESSWIRE4 months ago

    Cormedix Inc. Receives a Continued Listing Standard Notice from the NYSE American

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / June 19, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that on June 14, 2018, it received a notice from the NYSE American that, based on its Form 10-Q for the quarter ended March 31, 2018, filed on May 15, 2018, Cormedix does not meet a continued listing standard of the NYSE American as set forth in Part 10 of the NYSE American Company Guide.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! salesforce.com, inc. (NYSE: CRM ) stock was trading ...

  • ACCESSWIRE5 months ago

    CorMedix, Inc. Reports Progress on LOCK- IT 100 Data Review and Appoints Paul Chew as Consultant Advisor CMO

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / May 29, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the Company's clinical operations team has reviewed and source-verified more than 75% of data for the interim analysis of the Phase 3 LOCK-IT 100 study for Neutrolin®. The pace of source verification continues to accelerate, and the Company is on schedule to complete this work by the end of June 2018.

  • With A -26.58% Earnings Drop, Did CorMedix Inc (NYSEMKT:CRMD) Really Underperform?
    Simply Wall St.5 months ago

    With A -26.58% Earnings Drop, Did CorMedix Inc (NYSEMKT:CRMD) Really Underperform?

    When CorMedix Inc’s (AMEX:CRMD) announced its latest earnings (31 March 2018), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I used wereRead More...

  • ACCESSWIRE5 months ago

    Cormedix Inc. Reports First Quarter Financial Results and Provides Business Update

    - Anticipate Data Safety Monitoring Board Review of Interim Analysis in July 2018; Review was Triggered in December 2017 with 28 Confirmed Cases of Catheter-related Bloodstream Infections (CRBSIs) Identified ...

  • ACCESSWIRE5 months ago

    CorMedix Inc. to Report First Quarter 2018 Financial Results on Tuesday, May 15

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / May 9, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE6 months ago

    CorMedix Revises Timeline and Announces Changes to Lock-It-100 Study Management

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / April 27, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE7 months ago

    CorMedix Inc. Makes NYSE American Section 610(b) Public Announcement

    BEDMINSTER, NJ / ACCESSWIRE / March 20, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment ...